Collaboration between FESCA, SSoC and BI
Collaboration between FESCA, Scleroderma Society of Canada and Boehringer Ingelheim
In April, FESCA and the Scleroderma Society of Canada signed an agreement with Boehringer Ingelheim with the intention of working together to advance clinical research and improve awareness of systemic sclerosis (SSc) also known as scleroderma.
Called a Memorandum of Understanding, and written with the assistance and moderation of Eurordis, this agreement is not legally binding and is designed to be fully transparent to everyone. Its immediate goal is to include further patient expertise in the follow-through of a new ongoing trial called SENSCIS, which has been designed to understand if a drug approved for treatment of idiopathic lung fibrosis could also provide a benefit for patients with interstitial lung disease associated with SSc.
news & events
FESCA is delighted to announce that the next World Scleroderma Patient Congress, which takes place in Prague from March 5-7, 2020, will be live-streamed.
We invite you from all over the world to post a picture/video with smiles on social medias like twitter, facebook, instagram etc with the hashtag #ScleroSmile
PRESS RELEASE: European associations align in the battle against systemic sclerosis for World Scleroderma Day 2019